Narrow search
Showing 51 - 60 of 307,109
Cover Image
All that is Gold Does Not Glitter in Human Clinical Research : A Law-Policy Proposal to Brighten the Global 'Gold Standard' for Drug Research and Development
Malinowski, Michael J.; Gautreaux, Grant - 2012
the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use …
Persistent link: https://www.econbiz.de/10014163935
Cover Image
Cheap Drugs at What Price to Innovation : Does the Compulsory Licensing of Pharmaceuticals Hurt Innovation?
Chien, Colleen V. - 2014
The patent system is built on the premise that patents provide an incentive for innovation by offering a limited monopoly to patentees. The inverse assumption that removing patent protection will hurt innovation has largely prevented the widespread use of compulsory licensing - the practice of...
Persistent link: https://www.econbiz.de/10014029626
Cover Image
How does basic research improve innovation performance in the world's major pharmaceutical firms?
Leten, Bart; Kelchtermans, Stijn; Belderbos, René - In: Industry and innovation 29 (2022) 3, pp. 396-424
Persistent link: https://www.econbiz.de/10013170079
Cover Image
Financing vaccines for global health security
Vu, Jonathan T.; Kaplan, Benjamin K.; Chaudhuri, Shomesh; … - In: Journal of investment management : JOIM 20 (2022) 2, pp. 51-67
Persistent link: https://www.econbiz.de/10013433610
Cover Image
TRIPS flexibilities and access to medicines : an evaluation of barriers to employing compulsory licenses for patented pharmaceuticals at the WTO
Wong, Anna S. Y.; Cole, Clarke B.; Kohler, Jillian Clare - 2022
without the patent owner's authorization by issuing a compulsory license (CL). In the pharmaceuticals space, governments have … before patent expiry, increasing the supply and reducing the price of patented pharmaceuticals domestically. This paper … evaluates the three primary barriers to employing compulsory licenses for pharmaceuticals underscored by members during TRIPS …
Persistent link: https://www.econbiz.de/10013469578
Cover Image
Access to medicine versus test data exclusivity : safeguarding flexibilities under international law
Shaikh, Owais H. - 2016
Exclusivity and Access (IDEAS) -- National Laws -- Test Data Exclusivity in FTAs and Access to Originator Pharmaceuticals …
Persistent link: https://www.econbiz.de/10013447192
Cover Image
COVID-19 vaccines as global public goods : between life and profit
King, Katiuska; Carranza Barona, César - 2022
In the context of a health emergency like the COVID-19 pandemic, the global availability of and access to vaccines are imperative. This research paper provides an analysis from the perspective of international political economy, of the financing of COVID-19 vaccines and of the market strategies...
Persistent link: https://www.econbiz.de/10013194326
Cover Image
Changing Innovation in the Pharmaceutical Industry : Globalization and New Ways of Drug Development
Jungmittag, Andre - 2000
analyzes these new ways in drug development in pharmaceuticals within the concept of "national systems of innovations" as well …
Persistent link: https://www.econbiz.de/10013518480
Cover Image
Lessons from India's implementation of Doha Declaration on TRIPS and Public Health
Batra, Nanditta - 2022
pharmaceuticals. The US-led developed countries bloc argued in favour of patents for pharmaceuticals amidst opposition from Brazil … form of patents for pharmaceuticals, the developing countries were able to extract some procedural and substantive …
Persistent link: https://www.econbiz.de/10013393634
Cover Image
AIDS and Aid : A Public Good Approach
Sonntag, Diana - 2010
worldwide. Todd Sandler (2001a) Health concerns are ?rmly embedded in the developing world. Conditions of poverty like …, affect the well-being of people globally. Of all the health crises originating from the developing world the HIV …
Persistent link: https://www.econbiz.de/10013521335